<?xml version="1.0"?>
<rss version="2.0">
 <channel>
  <title>StreetInsider.com News Articles</title>
  <link>http://www.streetinsider.com</link>
  <description>Latest StreetInsider.com News Articles</description>
  <language>en-us</language>
  <copyright>Copyright 2026, StreetInsider.com</copyright>
  <managingEditor>rss@streetinsider.com (SI RSS)</managingEditor>
  <webMaster>rss@streetinsider.com (SI RSS)</webMaster>
  <lastBuildDate>Tue, 11 Aug 2026 16:30:00 -0400</lastBuildDate>
  <docs>http://blogs.law.harvard.edu/tech/rss</docs>
  <image>
   <url>http://www.streetinsider.com/images/rss_logo.gif</url>
   <title>StreetInsider.com News Articles</title>
   <link>http://www.streetinsider.com</link>
   <width>143</width>
   <height>28</height>
  </image>
  <skipHours>
   <hour>0</hour>
   <hour>1</hour>
   <hour>2</hour>
   <hour>3</hour>
   <hour>21</hour>
   <hour>22</hour>
   <hour>23</hour>
  </skipHours>
  <skipDays>
   <day>Saturday</day>
   <day>Sunday</day>
  </skipDays>
  <item>
   <title>Form  6-K        InMode Ltd.               For: Aug 11</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++InMode+Ltd.+++++++++++++++For%3A+Aug+11/26906307.html</link>
   <description>si-local-file:///var/storage/secattach/20260811/26906307.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++InMode+Ltd.+++++++++++++++For%3A+Aug+11/26906307.html</guid>
   <pubDate>Tue, 11 Aug 2026 16:30:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">INMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.41658003</category>
   	  </item>
  <item>
   <title>Form  6-K        InMode Ltd.               For: Aug 11</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++InMode+Ltd.+++++++++++++++For%3A+Aug+11/26906307.html</link>
   <description>si-local-file:///var/storage/secattach/20260811/26906307.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++InMode+Ltd.+++++++++++++++For%3A+Aug+11/26906307.html</guid>
   <pubDate>Tue, 11 Aug 2026 16:30:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">INMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.41658003</category>
   	  </item>
  <item>
   <title>Form  SCHEDULE 13D/A  InMode Ltd.                            Filed by: Mizrahy Moshe</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++InMode+Ltd.++++++++++++++++++++++++++++Filed+by%3A+Mizrahy+Moshe/26876323.html</link>
   <description>si-local-file:///var/storage/secattach/20260805/26876323.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++InMode+Ltd.++++++++++++++++++++++++++++Filed+by%3A+Mizrahy+Moshe/26876323.html</guid>
   <pubDate>Wed, 05 Aug 2026 18:10:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">INMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.41658003</category>
   	  </item>
  <item>
   <title>Form  SCHEDULE 13D/A  InMode Ltd.                            Filed by: Mizrahy Moshe</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++InMode+Ltd.++++++++++++++++++++++++++++Filed+by%3A+Mizrahy+Moshe/26876323.html</link>
   <description>si-local-file:///var/storage/secattach/20260805/26876323.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++InMode+Ltd.++++++++++++++++++++++++++++Filed+by%3A+Mizrahy+Moshe/26876323.html</guid>
   <pubDate>Wed, 05 Aug 2026 18:10:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">INMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.41658003</category>
   	  </item>
  <item>
   <title>Form  4          InMode Ltd.               For: Aug 04  Filed by: Itzkovich Moshe</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++4++++++++++InMode+Ltd.+++++++++++++++For%3A+Aug+04++Filed+by%3A+Itzkovich+Moshe/26873722.html</link>
   <description>si-local-file:///var/storage/secattach/20260805/26873722.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++4++++++++++InMode+Ltd.+++++++++++++++For%3A+Aug+04++Filed+by%3A+Itzkovich+Moshe/26873722.html</guid>
   <pubDate>Wed, 05 Aug 2026 16:04:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">INMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.41658003</category>
   	  </item>
  <item>
   <title>Form  4          InMode Ltd.               For: Aug 04  Filed by: Itzkovich Moshe</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++4++++++++++InMode+Ltd.+++++++++++++++For%3A+Aug+04++Filed+by%3A+Itzkovich+Moshe/26873722.html</link>
   <description>si-local-file:///var/storage/secattach/20260805/26873722.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++4++++++++++InMode+Ltd.+++++++++++++++For%3A+Aug+04++Filed+by%3A+Itzkovich+Moshe/26873722.html</guid>
   <pubDate>Wed, 05 Aug 2026 16:04:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">INMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.41658003</category>
   	  </item>
  <item>
   <title>InMode Ltd. (INMD) Tops Q3 EPS by 2c ; Offers Guidance</title>
   <link>http://www.streetinsider.com/Earnings/InMode+Ltd.+%28INMD%29+Tops+Q3+EPS+by+2c+%3B+Offers+Guidance/26870321.html</link>
   <description>&lt;p&gt;InMode Ltd. (NASDAQ: INMD) reported Q3 EPS of $0.35, $0.02 better than the analyst estimate of $0.33. Revenue for the quarter came in at $95.6 million versus the consensus estimate of $92.64 million.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;FY 2026 Outlook:-&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;Revenues between $365 million and $375 million vs consensus $370.3 million.&lt;br /&gt;Non-GAAP earnings per diluted share between $1.29 and $1.34 vs consensus $1.32.&lt;/p&gt;&lt;p&gt;For earnings history and earnings-related data on InMode Ltd. (INMD) &lt;a href=&quot;http://www.streetinsider.com/ec_earnings.php?q=INMD&quot;&gt;click here&lt;/a&gt;.&lt;/p&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Earnings/InMode+Ltd.+%28INMD%29+Tops+Q3+EPS+by+2c+%3B+Offers+Guidance/26870321.html</guid>
   <pubDate>Wed, 05 Aug 2026 07:31:01 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">INMD</category>
   	  </item>
  <item>
   <title>InMode Reports Second Quarter 2026 Financial Results: Quarterly GAAP Revenues of $95.6 Million, Consistent with the Second Quarter of 2025</title>
   <link>http://www.streetinsider.com/Press+Releases/InMode+Reports+Second+Quarter+2026+Financial+Results%3A+Quarterly+GAAP+Revenues+of+%2495.6+Million%2C+Consistent+with+the+Second+Quarter+of+2025/26869997.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;YOKNEAM, &lt;location value=&quot;LC/il&quot; idsrc=&quot;xmltag.org&quot; &gt;Israel&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;Aug. 5, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ --&lt;b&gt; &lt;span value=&quot;NASDAQ-NMS:INMD&quot; idsrc=&quot;xmltag.org&quot; &gt;InMode Ltd.&lt;/span&gt; &lt;/b&gt;(Nasdaq: INMD)&lt;b&gt; (&quot;&lt;span value=&quot;NASDAQ-NMS:INMD&quot; idsrc=&quot;xmltag.org&quot; &gt;InMode&lt;/span&gt;&quot;)&lt;/b&gt;, a leading global provider of innovative medical technologies, today announced its consolidated financial results for the second quarter of 2026.&lt;/p&gt;
&lt;div id=&quot;prni_dvprnejpg59aeleft&quot; dir=&quot;ltr&quot; style=&quot;width: 100%; text-align: left;&quot;&gt;&lt;img id=&quot;prnejpg59aeleft&quot; style=&quot;width: 400px; height: 223px;&quot; title=&quot;InMode Logo&quot; src=&quot;https://mma.prnewswire.com/media/1064477/InMode_Logo.jpg&quot; alt=&quot;InMode Logo&quot; align=&quot;middle&quot; /&gt;&lt;/div&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;Second Quarter 2026 Highlights:&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;ul type=&quot;disc&quot;&gt;&lt;li&gt;Quarterly GAAP revenues of &lt;money&gt;$95.6 million&lt;/money&gt;, consistent with the second quarter of 2025.&lt;/li&gt;&lt;li&gt;Quarterly revenues from consumables and service of &lt;money&gt;$22.3 million&lt;/money&gt;, an increase of 13% compared to the second quarter of 2025.&lt;/li&gt;&lt;li&gt;GAAP operating income of</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/InMode+Reports+Second+Quarter+2026+Financial+Results%3A+Quarterly+GAAP+Revenues+of+%2495.6+Million%2C+Consistent+with+the+Second+Quarter+of+2025/26869997.html</guid>
   <pubDate>Wed, 05 Aug 2026 07:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">INMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.41658003</category>
   	  </item>
  <item>
   <title>InMode Reports Second Quarter 2026 Financial Results: Quarterly GAAP Revenues of $95.6 Million, Consistent with the Second Quarter of 2025</title>
   <link>http://www.streetinsider.com/Press+Releases/InMode+Reports+Second+Quarter+2026+Financial+Results%3A+Quarterly+GAAP+Revenues+of+%2495.6+Million%2C+Consistent+with+the+Second+Quarter+of+2025/26869997.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;YOKNEAM, &lt;location value=&quot;LC/il&quot; idsrc=&quot;xmltag.org&quot; &gt;Israel&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;Aug. 5, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ --&lt;b&gt; &lt;span value=&quot;NASDAQ-NMS:INMD&quot; idsrc=&quot;xmltag.org&quot; &gt;InMode Ltd.&lt;/span&gt; &lt;/b&gt;(Nasdaq: INMD)&lt;b&gt; (&quot;&lt;span value=&quot;NASDAQ-NMS:INMD&quot; idsrc=&quot;xmltag.org&quot; &gt;InMode&lt;/span&gt;&quot;)&lt;/b&gt;, a leading global provider of innovative medical technologies, today announced its consolidated financial results for the second quarter of 2026.&lt;/p&gt;
&lt;div id=&quot;prni_dvprnejpg59aeleft&quot; dir=&quot;ltr&quot; style=&quot;width: 100%; text-align: left;&quot;&gt;&lt;img id=&quot;prnejpg59aeleft&quot; style=&quot;width: 400px; height: 223px;&quot; title=&quot;InMode Logo&quot; src=&quot;https://mma.prnewswire.com/media/1064477/InMode_Logo.jpg&quot; alt=&quot;InMode Logo&quot; align=&quot;middle&quot; /&gt;&lt;/div&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;Second Quarter 2026 Highlights:&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;ul type=&quot;disc&quot;&gt;&lt;li&gt;Quarterly GAAP revenues of &lt;money&gt;$95.6 million&lt;/money&gt;, consistent with the second quarter of 2025.&lt;/li&gt;&lt;li&gt;Quarterly revenues from consumables and service of &lt;money&gt;$22.3 million&lt;/money&gt;, an increase of 13% compared to the second quarter of 2025.&lt;/li&gt;&lt;li&gt;GAAP operating income of</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/InMode+Reports+Second+Quarter+2026+Financial+Results%3A+Quarterly+GAAP+Revenues+of+%2495.6+Million%2C+Consistent+with+the+Second+Quarter+of+2025/26869997.html</guid>
   <pubDate>Wed, 05 Aug 2026 07:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">INMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.41658003</category>
   	  </item>
  <item>
   <title>InMode Reports Second Quarter 2026 Financial Results: Quarterly GAAP Revenues of $95.6 Million, Consistent with the Second Quarter of 2025</title>
   <link>http://www.streetinsider.com/PRNewswire/InMode+Reports+Second+Quarter+2026+Financial+Results%3A+Quarterly+GAAP+Revenues+of+%2495.6+Million%2C+Consistent+with+the+Second+Quarter+of+2025/26869997.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;YOKNEAM, &lt;location value=&quot;LC/il&quot; idsrc=&quot;xmltag.org&quot; &gt;Israel&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;Aug. 5, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ --&lt;b&gt; &lt;span value=&quot;NASDAQ-NMS:INMD&quot; idsrc=&quot;xmltag.org&quot; &gt;InMode Ltd.&lt;/span&gt; &lt;/b&gt;(Nasdaq: INMD)&lt;b&gt; (&quot;&lt;span value=&quot;NASDAQ-NMS:INMD&quot; idsrc=&quot;xmltag.org&quot; &gt;InMode&lt;/span&gt;&quot;)&lt;/b&gt;, a leading global provider of innovative medical technologies, today announced its consolidated financial results for the second quarter of 2026.&lt;/p&gt;
&lt;div id=&quot;prni_dvprnejpg59aeleft&quot; dir=&quot;ltr&quot; style=&quot;width: 100%; text-align: left;&quot;&gt;&lt;img id=&quot;prnejpg59aeleft&quot; style=&quot;width: 400px; height: 223px;&quot; title=&quot;InMode Logo&quot; src=&quot;https://mma.prnewswire.com/media/1064477/InMode_Logo.jpg&quot; alt=&quot;InMode Logo&quot; align=&quot;middle&quot; /&gt;&lt;/div&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;Second Quarter 2026 Highlights:&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;ul type=&quot;disc&quot;&gt;&lt;li&gt;Quarterly GAAP revenues of &lt;money&gt;$95.6 million&lt;/money&gt;, consistent with the second quarter of 2025.&lt;/li&gt;&lt;li&gt;Quarterly revenues from consumables and service of &lt;money&gt;$22.3 million&lt;/money&gt;, an increase of 13% compared to the second quarter of 2025.&lt;/li&gt;&lt;li&gt;GAAP operating income of</description>
   <guid isPermaLink="true">http://www.streetinsider.com/PRNewswire/InMode+Reports+Second+Quarter+2026+Financial+Results%3A+Quarterly+GAAP+Revenues+of+%2495.6+Million%2C+Consistent+with+the+Second+Quarter+of+2025/26869997.html</guid>
   <pubDate>Wed, 05 Aug 2026 07:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">INMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.41658003</category>
   	  </item>
  <item>
   <title>InMode Reports Second Quarter 2026 Financial Results: Quarterly GAAP Revenues of $95.6 Million, Consistent with the Second Quarter of 2025</title>
   <link>http://www.streetinsider.com/PRNewswire/InMode+Reports+Second+Quarter+2026+Financial+Results%3A+Quarterly+GAAP+Revenues+of+%2495.6+Million%2C+Consistent+with+the+Second+Quarter+of+2025/26869997.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;YOKNEAM, &lt;location value=&quot;LC/il&quot; idsrc=&quot;xmltag.org&quot; &gt;Israel&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;Aug. 5, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ --&lt;b&gt; &lt;span value=&quot;NASDAQ-NMS:INMD&quot; idsrc=&quot;xmltag.org&quot; &gt;InMode Ltd.&lt;/span&gt; &lt;/b&gt;(Nasdaq: INMD)&lt;b&gt; (&quot;&lt;span value=&quot;NASDAQ-NMS:INMD&quot; idsrc=&quot;xmltag.org&quot; &gt;InMode&lt;/span&gt;&quot;)&lt;/b&gt;, a leading global provider of innovative medical technologies, today announced its consolidated financial results for the second quarter of 2026.&lt;/p&gt;
&lt;div id=&quot;prni_dvprnejpg59aeleft&quot; dir=&quot;ltr&quot; style=&quot;width: 100%; text-align: left;&quot;&gt;&lt;img id=&quot;prnejpg59aeleft&quot; style=&quot;width: 400px; height: 223px;&quot; title=&quot;InMode Logo&quot; src=&quot;https://mma.prnewswire.com/media/1064477/InMode_Logo.jpg&quot; alt=&quot;InMode Logo&quot; align=&quot;middle&quot; /&gt;&lt;/div&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;Second Quarter 2026 Highlights:&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;ul type=&quot;disc&quot;&gt;&lt;li&gt;Quarterly GAAP revenues of &lt;money&gt;$95.6 million&lt;/money&gt;, consistent with the second quarter of 2025.&lt;/li&gt;&lt;li&gt;Quarterly revenues from consumables and service of &lt;money&gt;$22.3 million&lt;/money&gt;, an increase of 13% compared to the second quarter of 2025.&lt;/li&gt;&lt;li&gt;GAAP operating income of</description>
   <guid isPermaLink="true">http://www.streetinsider.com/PRNewswire/InMode+Reports+Second+Quarter+2026+Financial+Results%3A+Quarterly+GAAP+Revenues+of+%2495.6+Million%2C+Consistent+with+the+Second+Quarter+of+2025/26869997.html</guid>
   <pubDate>Wed, 05 Aug 2026 07:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">INMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.41658003</category>
   	  </item>
  <item>
   <title>Form  6-K        InMode Ltd.               For: Aug 05</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++InMode+Ltd.+++++++++++++++For%3A+Aug+05/26870016.html</link>
   <description>si-local-file:///var/storage/secattach/20260805/26870016.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++InMode+Ltd.+++++++++++++++For%3A+Aug+05/26870016.html</guid>
   <pubDate>Wed, 05 Aug 2026 07:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">INMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.41658003</category>
   	  </item>
  <item>
   <title>Form  6-K        InMode Ltd.               For: Aug 05</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++InMode+Ltd.+++++++++++++++For%3A+Aug+05/26870016.html</link>
   <description>si-local-file:///var/storage/secattach/20260805/26870016.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++InMode+Ltd.+++++++++++++++For%3A+Aug+05/26870016.html</guid>
   <pubDate>Wed, 05 Aug 2026 07:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">INMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.41658003</category>
   	  </item>
  <item>
   <title>Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One</title>
   <link>http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html</link>
   <description>&lt;p&gt;&lt;strong&gt;Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU)&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;NEW YORK, Aug.  04, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=LrF4u_nq-M6rhKWRIFzyXu_SqHTmlF2LhuF9syLwk8f08DOVrOInZfGu4xhPcOF3GuPEXiVog2j84gNMhsUSgzuPzAL58AtKcaJ1ABt3xUc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;American News Group&lt;/a&gt; &lt;strong&gt;News Commentary&lt;/strong&gt; - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator category that Botox&lt;sup&gt;®&lt;/sup&gt; created. The hyaluronic-acid filler category. The biostimulator category. Each turned a novel way of treating the face into a franchise measured in billions, and the companies that own those categories, from AbbVie (NYSE: ABBV) and Johnson &amp;amp; Johnson (NYSE: JNJ) to InMode (Nasdaq: INMD) and Anika Therapeutics (Nasdaq: ANIK), built enormous businesses around them. Now</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html</guid>
   <pubDate>Tue, 04 Aug 2026 09:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ABBV</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ABBV</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ANIK</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ANIK</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">INMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">INMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
   	  </item>
  <item>
   <title>Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One</title>
   <link>http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html</link>
   <description>&lt;p&gt;&lt;strong&gt;Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU)&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;NEW YORK, Aug.  04, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=LrF4u_nq-M6rhKWRIFzyXu_SqHTmlF2LhuF9syLwk8f08DOVrOInZfGu4xhPcOF3GuPEXiVog2j84gNMhsUSgzuPzAL58AtKcaJ1ABt3xUc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;American News Group&lt;/a&gt; &lt;strong&gt;News Commentary&lt;/strong&gt; - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator category that Botox&lt;sup&gt;®&lt;/sup&gt; created. The hyaluronic-acid filler category. The biostimulator category. Each turned a novel way of treating the face into a franchise measured in billions, and the companies that own those categories, from AbbVie (NYSE: ABBV) and Johnson &amp;amp; Johnson (NYSE: JNJ) to InMode (Nasdaq: INMD) and Anika Therapeutics (Nasdaq: ANIK), built enormous businesses around them. Now</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html</guid>
   <pubDate>Tue, 04 Aug 2026 09:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ABBV</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ABBV</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ANIK</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ANIK</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">INMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">INMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
   	  </item>
  <item>
   <title>Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One</title>
   <link>http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html</link>
   <description>&lt;p&gt;&lt;strong&gt;Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU)&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;NEW YORK, Aug.  04, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=LrF4u_nq-M6rhKWRIFzyXu_SqHTmlF2LhuF9syLwk8f08DOVrOInZfGu4xhPcOF3GuPEXiVog2j84gNMhsUSgzuPzAL58AtKcaJ1ABt3xUc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;American News Group&lt;/a&gt; &lt;strong&gt;News Commentary&lt;/strong&gt; - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator category that Botox&lt;sup&gt;®&lt;/sup&gt; created. The hyaluronic-acid filler category. The biostimulator category. Each turned a novel way of treating the face into a franchise measured in billions, and the companies that own those categories, from AbbVie (NYSE: ABBV) and Johnson &amp;amp; Johnson (NYSE: JNJ) to InMode (Nasdaq: INMD) and Anika Therapeutics (Nasdaq: ANIK), built enormous businesses around them. Now</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html</guid>
   <pubDate>Tue, 04 Aug 2026 09:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ABBV</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ABBV</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ANIK</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ANIK</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">INMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">INMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
   	  </item>
  <item>
   <title>Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One</title>
   <link>http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html</link>
   <description>&lt;p&gt;&lt;strong&gt;Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU)&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;NEW YORK, Aug.  04, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=LrF4u_nq-M6rhKWRIFzyXu_SqHTmlF2LhuF9syLwk8f08DOVrOInZfGu4xhPcOF3GuPEXiVog2j84gNMhsUSgzuPzAL58AtKcaJ1ABt3xUc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;American News Group&lt;/a&gt; &lt;strong&gt;News Commentary&lt;/strong&gt; - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator category that Botox&lt;sup&gt;®&lt;/sup&gt; created. The hyaluronic-acid filler category. The biostimulator category. Each turned a novel way of treating the face into a franchise measured in billions, and the companies that own those categories, from AbbVie (NYSE: ABBV) and Johnson &amp;amp; Johnson (NYSE: JNJ) to InMode (Nasdaq: INMD) and Anika Therapeutics (Nasdaq: ANIK), built enormous businesses around them. Now</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html</guid>
   <pubDate>Tue, 04 Aug 2026 09:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ABBV</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ABBV</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ANIK</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ANIK</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">INMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">INMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
   	  </item>
  <item>
   <title>Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One</title>
   <link>http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html</link>
   <description>&lt;p&gt;&lt;strong&gt;Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU)&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;NEW YORK, Aug.  04, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=LrF4u_nq-M6rhKWRIFzyXu_SqHTmlF2LhuF9syLwk8f08DOVrOInZfGu4xhPcOF3GuPEXiVog2j84gNMhsUSgzuPzAL58AtKcaJ1ABt3xUc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;American News Group&lt;/a&gt; &lt;strong&gt;News Commentary&lt;/strong&gt; - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator category that Botox&lt;sup&gt;®&lt;/sup&gt; created. The hyaluronic-acid filler category. The biostimulator category. Each turned a novel way of treating the face into a franchise measured in billions, and the companies that own those categories, from AbbVie (NYSE: ABBV) and Johnson &amp;amp; Johnson (NYSE: JNJ) to InMode (Nasdaq: INMD) and Anika Therapeutics (Nasdaq: ANIK), built enormous businesses around them. Now</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html</guid>
   <pubDate>Tue, 04 Aug 2026 09:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ABBV</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ABBV</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ANIK</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ANIK</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">INMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">INMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
   	  </item>
  <item>
   <title>Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One</title>
   <link>http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html</link>
   <description>&lt;p&gt;&lt;strong&gt;Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU)&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;NEW YORK, Aug.  04, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=LrF4u_nq-M6rhKWRIFzyXu_SqHTmlF2LhuF9syLwk8f08DOVrOInZfGu4xhPcOF3GuPEXiVog2j84gNMhsUSgzuPzAL58AtKcaJ1ABt3xUc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;American News Group&lt;/a&gt; &lt;strong&gt;News Commentary&lt;/strong&gt; - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator category that Botox&lt;sup&gt;®&lt;/sup&gt; created. The hyaluronic-acid filler category. The biostimulator category. Each turned a novel way of treating the face into a franchise measured in billions, and the companies that own those categories, from AbbVie (NYSE: ABBV) and Johnson &amp;amp; Johnson (NYSE: JNJ) to InMode (Nasdaq: INMD) and Anika Therapeutics (Nasdaq: ANIK), built enormous businesses around them. Now</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html</guid>
   <pubDate>Tue, 04 Aug 2026 09:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ABBV</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ABBV</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ANIK</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ANIK</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">INMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">INMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
   	  </item>
  <item>
   <title>Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One</title>
   <link>http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html</link>
   <description>&lt;p&gt;&lt;strong&gt;Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU)&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;NEW YORK, Aug.  04, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=LrF4u_nq-M6rhKWRIFzyXu_SqHTmlF2LhuF9syLwk8f08DOVrOInZfGu4xhPcOF3GuPEXiVog2j84gNMhsUSgzuPzAL58AtKcaJ1ABt3xUc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;American News Group&lt;/a&gt; &lt;strong&gt;News Commentary&lt;/strong&gt; - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator category that Botox&lt;sup&gt;®&lt;/sup&gt; created. The hyaluronic-acid filler category. The biostimulator category. Each turned a novel way of treating the face into a franchise measured in billions, and the companies that own those categories, from AbbVie (NYSE: ABBV) and Johnson &amp;amp; Johnson (NYSE: JNJ) to InMode (Nasdaq: INMD) and Anika Therapeutics (Nasdaq: ANIK), built enormous businesses around them. Now</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html</guid>
   <pubDate>Tue, 04 Aug 2026 09:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ABBV</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ABBV</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ANIK</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ANIK</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">INMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">INMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
   	  </item>
  <item>
   <title>Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One</title>
   <link>http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html</link>
   <description>&lt;p&gt;&lt;strong&gt;Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU)&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;NEW YORK, Aug.  04, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=LrF4u_nq-M6rhKWRIFzyXu_SqHTmlF2LhuF9syLwk8f08DOVrOInZfGu4xhPcOF3GuPEXiVog2j84gNMhsUSgzuPzAL58AtKcaJ1ABt3xUc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;American News Group&lt;/a&gt; &lt;strong&gt;News Commentary&lt;/strong&gt; - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator category that Botox&lt;sup&gt;®&lt;/sup&gt; created. The hyaluronic-acid filler category. The biostimulator category. Each turned a novel way of treating the face into a franchise measured in billions, and the companies that own those categories, from AbbVie (NYSE: ABBV) and Johnson &amp;amp; Johnson (NYSE: JNJ) to InMode (Nasdaq: INMD) and Anika Therapeutics (Nasdaq: ANIK), built enormous businesses around them. Now</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html</guid>
   <pubDate>Tue, 04 Aug 2026 09:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ABBV</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ABBV</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ANIK</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ANIK</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">INMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">INMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
   	  </item>
  <item>
   <title>Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One</title>
   <link>http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html</link>
   <description>&lt;p&gt;&lt;strong&gt;Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU)&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;NEW YORK, Aug.  04, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=LrF4u_nq-M6rhKWRIFzyXu_SqHTmlF2LhuF9syLwk8f08DOVrOInZfGu4xhPcOF3GuPEXiVog2j84gNMhsUSgzuPzAL58AtKcaJ1ABt3xUc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;American News Group&lt;/a&gt; &lt;strong&gt;News Commentary&lt;/strong&gt; - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator category that Botox&lt;sup&gt;®&lt;/sup&gt; created. The hyaluronic-acid filler category. The biostimulator category. Each turned a novel way of treating the face into a franchise measured in billions, and the companies that own those categories, from AbbVie (NYSE: ABBV) and Johnson &amp;amp; Johnson (NYSE: JNJ) to InMode (Nasdaq: INMD) and Anika Therapeutics (Nasdaq: ANIK), built enormous businesses around them. Now</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html</guid>
   <pubDate>Tue, 04 Aug 2026 09:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ABBV</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ABBV</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ANIK</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ANIK</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">INMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">INMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
   	  </item>
  <item>
   <title>Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One</title>
   <link>http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html</link>
   <description>&lt;p&gt;&lt;strong&gt;Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU)&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;NEW YORK, Aug.  04, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=LrF4u_nq-M6rhKWRIFzyXu_SqHTmlF2LhuF9syLwk8f08DOVrOInZfGu4xhPcOF3GuPEXiVog2j84gNMhsUSgzuPzAL58AtKcaJ1ABt3xUc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;American News Group&lt;/a&gt; &lt;strong&gt;News Commentary&lt;/strong&gt; - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator category that Botox&lt;sup&gt;®&lt;/sup&gt; created. The hyaluronic-acid filler category. The biostimulator category. Each turned a novel way of treating the face into a franchise measured in billions, and the companies that own those categories, from AbbVie (NYSE: ABBV) and Johnson &amp;amp; Johnson (NYSE: JNJ) to InMode (Nasdaq: INMD) and Anika Therapeutics (Nasdaq: ANIK), built enormous businesses around them. Now</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html</guid>
   <pubDate>Tue, 04 Aug 2026 09:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ABBV</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ABBV</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ANIK</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ANIK</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">INMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">INMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
   	  </item>
  <item>
   <title>Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One</title>
   <link>http://www.streetinsider.com/Globe+Newswire/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html</link>
   <description>&lt;p&gt;&lt;strong&gt;Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU)&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;NEW YORK, Aug.  04, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=LrF4u_nq-M6rhKWRIFzyXu_SqHTmlF2LhuF9syLwk8f08DOVrOInZfGu4xhPcOF3GuPEXiVog2j84gNMhsUSgzuPzAL58AtKcaJ1ABt3xUc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;American News Group&lt;/a&gt; &lt;strong&gt;News Commentary&lt;/strong&gt; - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator category that Botox&lt;sup&gt;®&lt;/sup&gt; created. The hyaluronic-acid filler category. The biostimulator category. Each turned a novel way of treating the face into a franchise measured in billions, and the companies that own those categories, from AbbVie (NYSE: ABBV) and Johnson &amp;amp; Johnson (NYSE: JNJ) to InMode (Nasdaq: INMD) and Anika Therapeutics (Nasdaq: ANIK), built enormous businesses around them. Now</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html</guid>
   <pubDate>Tue, 04 Aug 2026 09:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ABBV</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ABBV</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ANIK</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ANIK</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">INMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">INMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
   	  </item>
  <item>
   <title>Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One</title>
   <link>http://www.streetinsider.com/Globe+Newswire/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html</link>
   <description>&lt;p&gt;&lt;strong&gt;Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU)&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;NEW YORK, Aug.  04, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=LrF4u_nq-M6rhKWRIFzyXu_SqHTmlF2LhuF9syLwk8f08DOVrOInZfGu4xhPcOF3GuPEXiVog2j84gNMhsUSgzuPzAL58AtKcaJ1ABt3xUc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;American News Group&lt;/a&gt; &lt;strong&gt;News Commentary&lt;/strong&gt; - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator category that Botox&lt;sup&gt;®&lt;/sup&gt; created. The hyaluronic-acid filler category. The biostimulator category. Each turned a novel way of treating the face into a franchise measured in billions, and the companies that own those categories, from AbbVie (NYSE: ABBV) and Johnson &amp;amp; Johnson (NYSE: JNJ) to InMode (Nasdaq: INMD) and Anika Therapeutics (Nasdaq: ANIK), built enormous businesses around them. Now</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html</guid>
   <pubDate>Tue, 04 Aug 2026 09:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ABBV</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ABBV</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ANIK</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ANIK</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">INMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">INMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
   	  </item>
 </channel>
</rss>
